About Iovance Biotherapeutics
Iovance Biotherapeutics is a company based in San Carlos (United States) founded in 2007 by Robert T Brooke. It operates as a HealthTech. The company has 838 employees as of December 31, 2024. Iovance Biotherapeutics has completed 1 acquisition, including Proleukin. Iovance Biotherapeutics offers products and services including Amtagvi and Proleukin. Iovance Biotherapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter San Carlos, United States
- Employees 838 as on 31 Dec, 2024
- Founders Robert T Brooke
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Iovance Biotherapeutics, Inc.
-
Annual Revenue
$164.07 M (USD)13698.99as on Dec 31, 2024
-
Net Profit
-$372.18 M (USD)16.18as on Dec 31, 2024
-
EBITDA
-$351.67 M (USD)17.72as on Dec 31, 2024
-
Latest Funding Round
$100 M (USD), Post-IPO
Jun 15, 2016
-
Investors
Orbimed
& 2 more
-
Employee Count
838
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Iovance Biotherapeutics
Iovance Biotherapeutics is a publicly listed company on the NASDAQ with ticker symbol IOVA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Iovance Biotherapeutics
Iovance Biotherapeutics offers a comprehensive portfolio of products and services, including Amtagvi and Proleukin.
Amtagvi is developed for advanced cancer treatment therapies.
Proleukin is utilized in cancer immunotherapy treatment solutions.
People of Iovance Biotherapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
35 people
Operations Team
14 people
Software Development Team
12 people
Legal and Compliance
6 people
Human Resources and Administration
4 people
Senior Team
4 people
Product Management Team
3 people
Manufacturing Team
3 people
Unlock access to complete
Funding Insights of Iovance Biotherapeutics
Investors in Iovance Biotherapeutics
Iovance Biotherapeutics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Frazier Healthcare Partners and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare sector private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for Iovance Biotherapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Iovance Biotherapeutics
Iovance Biotherapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Proleukin.
Investment portfolio details for Iovance Biotherapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Information on cancer drugs is provided via an online platform.
|
Locked | Locked | 1998 | Locked |
Complete acquisition details for Iovance Biotherapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Iovance Biotherapeutics
Detailed financials for Iovance Biotherapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Iovance Biotherapeutics Comparisons
Peer comparison for Iovance Biotherapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Iovance Biotherapeutics
Iovance Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| Locked | Locked | Locked |
Targeted therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
Detailed competitors of Iovance Biotherapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Iovance Biotherapeutics
Complete news archive for Iovance Biotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Iovance Biotherapeutics
Iovance Biotherapeutics was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Iovance Biotherapeutics is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
Robert T Brooke is the current CEO of Iovance Biotherapeutics. They have also founded this company.
As of Dec 31, 2024, the latest employee count at Iovance Biotherapeutics is 838.
Annual revenue of Iovance Biotherapeutics is $164.07M as on Dec 31, 2024.
Iovance Biotherapeutics is engaged in pioneering cancer treatment by leveraging the human immune system. The company is dedicated to developing Tumor Infiltrating Lymphocyte (TIL) therapies and Peripheral Blood Lymphocyte (PBL) therapies for solid tumors and blood cancers. Solutions are personalized to target diverse cancer cells unique to each patient. Research and clinical trials are conducted across multiple advanced cancer types, including melanoma, NSCLC, and endometrial cancer. Manufacturing is supported by a state-of-the-art facility in Philadelphia. The focus is placed on next-generation approaches to enhance cancer treatment outcomes.
Iovance Biotherapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and argenx.
Iovance Biotherapeutics offers Amtagvi and Proleukin.
Yes, Iovance Biotherapeutics is publicly traded on NASDAQ under the ticker symbol IOVA.
Iovance Biotherapeutics has made 1 acquisition, including Proleukin.
Iovance Biotherapeutics has 3 investors. Key investors include Orbimed, Frazier Healthcare Partners, and Perceptive Advisors.
The ticker symbol of Iovance Biotherapeutics is IOVA on NASDAQ.